Company / Free Cash Flow
Myriad Genetics, Inc. Free Cash Flow History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$151.6M
FY2022
5-year range
-$151.6M / $600.0K
FY2018-FY2022
Trend
-25366.7%
vs FY2021
Sector context
#132 of 194
Health Care
What the data says
Free Cash Flow changed -25367% YoY in FY2022, a notable deviation from the 6-year average annual change of -4259%.
Based on SEC 10-K filings.
-$152M in FY2022.
Declined from $51M to -$152M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#132 of 194 in Health CareTop 68% of 194This company -$151.6M Sector average $470.8M
▼
-132.2% below sector average
Key checks
Key Insights
- Myriad Genetics, Inc.'s free cash flow has declined for 4 consecutive years.
- In FY2022, free cash flow decreased 25366.7% year-over-year.
- Ranks #132 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | -$151.6M | -25366.7% |
| FY2021 | $600.0K | -98.8% |
| FY2020 | $50.5M | -49.6% |
| FY2019 | $100.1M | -6.9% |
| FY2018 | $107.5M | +7.4% |
| FY2017 | $100.1M | -37.9% |
| FY2016 | $161.3M | +38.3% |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026